In the fourth year of its war with Russia, Ukraine for the first time seems ready to implement protective measures against an incoming nuclear attack.
Ordered Anti-Radioactivity Drugs
More specifically, and according to international media reports, the Ukrainian political leadership feels the need to prepare for a future nuclear disaster. One of the main reasons behind this decision is the existence and operation of several nuclear power plants, as well as the increasing threats from Moscow.
Given this, the Ukrainian government recently signed an agreement with the Israeli pharmaceutical company Pluri for the supply of a large stock of anti-radiation drugs. This drug is called PLX-R18 and was developed specifically for people who have been exposed to radiation and have been “poisoned” by it.
The drug PLX-R18 is administered to patients who are in critical condition and whose lives are at risk after extensive exposure to radiation.
Political and military analysts believe that the Russian-Ukrainian war is currently going through a critical period, which means that the tension could escalate by the minute. The expert community cannot completely rule out the possibility of a nuclear catastrophe.
This scenario could very easily become a reality: either if the Russian military were to bomb one of the many nuclear plants in Ukraine, or if Moscow itself were to use nuclear weapons against Ukrainian targets.
To prepare for this nightmare scenario, Kiev has decided to sign a major agreement with the Israeli company Pluristem, headquartered in Haifa. The agreement explicitly states that the drugs produced by the company will be transferred for storage in a special section of the Ukrainian blood bank Hemafund.
Pluristem and Hemafund are expected to cooperate further in the field of combating toxic radiation. The two companies must first conduct advanced clinical trials before the new Israeli drug can be used on patients in Ukraine.
However, reports claim that the contract signed by the two entities contains huge amounts of money. Both Pluristem and Hemafund are expected to earn more than $100 million each.
